Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by Boolishon Oct 16, 2013 8:28pm
214 Views
Post# 21822020

See You At 8.50

See You At 8.50

Why do an unpriced offering? Always gives the shorts/predatory longs a good reason to sit on it until they get their number.

Tekmira plans to arrange share offering

2013-10-16 16:08 ET - News Release

 

Ms. Jodi Regts reports

TEKMIRA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Tekmira Pharmaceuticals Corp. intends to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase up to an additional 15 per cent of the shares of common stock sold in the public offering to cover overallotments, if any. The company intends to use the net proceeds from the offering to finance working capital and general corporate purposes, including, but not limited to, progressing its research and development programs, including various collaborative arrangements, as well as advancing and progressing its LNP technology. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Stifel is acting as the sole book-running manager for the offering. Maxim Group LLC is acting as co-manager.

The offering is being made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission and a corresponding Canadian base-shelf prospectus filed with the securities regulatory authority in each of the provinces of Canada, except Quebec. A preliminary prospectus supplement relating to the offering will be filed with the SEC and with the securities regulatory authority in each of the provinces of Canada, except Quebec. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying base-shelf prospectus, copies of which may be obtained, when available, from Stifel, Nicolaus & Company Inc. by mail at 1 Montgomery St., 36th floor, San Francisco, Calif., 94104, by telephone at 415-364-2720 or by e-mail at syndprospectus@stifel.com, or on SEC's website or at SEDAR.

We seek Safe Harbor.

© 2013 Canjex Publishing Ltd. All rights reserved.


Bullboard Posts